Skip to main content
NIH funding notice PAR-24-197

HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)

Closed on December 10, 2024.

Posted
April 17, 2024
Close date
December 10, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $326,930 in first-year total cost, median $163,465.

Most frequent study sections

  1. Molecular Neurogenetics Study Section[MNG]1
  2. Surgery, Anesthesiology and Trauma Study Section[SAT]1

Most frequent institutions

  1. STANFORD UNIVERSITY1
  2. UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR1
Competing awards under PAR-24-197 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Role of PRR14 in Human Sensory Neurons in Oxaliplatin-Induced Peripheral Neuropathy1R03TR005864-01ALLES, SASCHA RDE LA PENA, JUNE BRYANUNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM$170,100MNG
2025Deciphering the role of dipeptidase 2 (DPEP2) to treat surgical pain1R03NS147020-01GROSS, ERIC RICHARDSTANFORD UNIVERSITY, CA$156,830SAT

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-24-197: HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed) | ScienceDex | ConductScience